Indiana taps NHIN to share public health data with CDC

Indiana has become the first state to use the Nationwide Health Information Network (NHIN) to convey public health information to the U.S. Centers for Disease Control and Prevention (CDC).

In the transmission, de-identified information on new cases of influenza, pneumonia and influenza-like illness was gathered from 76 emergency departments (EDs) across the state and sent to CDC by the Indianapolis-based Regenstrief Institute on behalf of the Indiana State Department of Health (ISDH).

The NHIN facilitates sharing of data simultaneously with the ISDH and, with state concurrence, CDC. This type of data sharing can result in more timely identification and characterization of emerging public health events that cross state boundaries and may lead to improved multi-state and federal situation awareness, according to Indiana University School of Medicine (IUSM) located, along with Regenstrief Institute, on the campus of Indiana University-Purdue University Indianapolis (IUPUI).

The NHIN enables secure health information exchange (HIE) over the internet and provides a foundation for the exchange of health information within communities and across the country. CDC has been a critical partner at the table with other federal agencies to ensure that the NHIN can be used to support ongoing efforts at state and national levels to improve surveillance of disease, IUSM stated.

According to IUSM, CDC, along with other federal partners, supports the emerging NHIN for enabling greater access to healthcare and public health information.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.